This content is machine translated Older patients with atopic dermatitis Why the Use of Biologics Is Recommended In light of demographic trends, an increase in the prevalence of atopic dermatitis is also being observed among the elderly population. Tailored treatment plans take into account a wide range...…
View Post 5 min This content is machine translated Highlights from the AAD Annual Meeting Atopic Dermatitis: Interesting News on Drug Candidates in Phase III At the 2026 Annual Meeting of the American Academy of Dermatology (AAD), the latest study data on amlitelimab and rademikibart, among other topics, were presented during Late-Breaking Research sessions. The...…
View Post 7 min This content is machine translated Atopic dermatitis as a door opener for an atopic cascade? AD trajectories: Summary of current findings Epidemiologic analyses and longitudinal studies show that the majority of infants affected by AD are symptom-free as adults, but in some, AD persists into adulthood. This is associated with an...…
View Post 5 min This content is machine translated Moderate to severe atopic dermatitis Established and novel biologics – the therapeutic landscape is in flux Clinically, atopic dermatitis (AD) manifests itself through a polymorphic picture of efflorescences, with pruritus and xerosis in the foreground. In addition to the antibody therapies dupilumab, tralokinumab and lebrikizumab, which...…
View Post 6 min This content is machine translated Atopic dermatitis: proven therapeutic principles and innovations From healthcare research to precision medicine In Switzerland, around 20 percent of children are affected by atopic eczema, compared to 4-5 percent of adults. The disease burden of AD is considerable, which is also related to...…
View Post 7 min This content is machine translated Prurigo nodularis and AD Effective itch relief through inhibition of the IL-31 signaling pathway The vicious circle of itching and scratching is a central element in both prurigo nodularis (PN) and atopic dermatitis (AD). Interleukin (IL)-31, often referred to as the “itch cytokine”, has...…
View Post 2 min This content is machine translated TREATswitzerland Register Evaluation of system therapies for AD In addition to conventional immunosuppressants, several monoclonal antibodies (biologics) and Janus kinase inhibitors (JAK-i) are now approved for the systemic treatment of atopic dermatitis (AD) in Switzerland. The primary objective...…
View Post 9 min This content is machine translated SID Annual Meeting: Highlights Update on inflammatory dermatoses – a concentrated load of innovative power Research teams from different corners of the world presented studies that are characterized by a high level of innovation. In addition to the evaluation of already established therapy options, numerous...…
View Post 8 min This content is machine translated Atopic dermatitis Implement the “minimal disease activity” concept Minimal disease activity (MDA) in atopic dermatitis (AD) is a concept that combines a treat-to-target therapeutic strategy with the principle of shared decision-making. The aim is to achieve a state...…
View Post 12 min This content is machine translated Atopic dermatitis Clinic, therapy and prevention in early childhood Atopic dermatitis is the most common chronic inflammatory skin disease in early childhood and is caused by a complex interaction of genetic and environmental factors. The quality of life of...… CME-Test
View Post 7 min This content is machine translated Atopic dermatitis and allergies Atopic dermatitis and allergies Type 2 inflammation and other factors Atopic patients are prone to immediate-type allergies and many studies show a correlation between sensitization to aeroallergens and exacerbations of atopic dermatitis (AD). A common characteristic of atopic diseases is...…
